Abstract
Ten healthy male volunteers received a single oral dose (50mg tablet) of a potential memory-enhancing compound, CL 275 838 administered once after fasting and once with a standard breakfast, in an open, crossover study. Plasma concentrations of unchanged drug, its debenzylated derivative (compound II, the main metabolite) and metabolite IV were measured by liquid chromatography using postcolumn photolysis and fluorometric detection and the calculated pharmacokinetic parameters were compared.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
